Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Jung Yong | - |
dc.contributor.author | Ryu, Kyung Ju | - |
dc.contributor.author | Park, Chaehwa | - |
dc.contributor.author | Hong, Mineui | - |
dc.contributor.author | Ko, Young Hyeh | - |
dc.contributor.author | Kim, Won Seog | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.date.accessioned | 2024-01-09T01:04:46Z | - |
dc.date.available | 2024-01-09T01:04:46Z | - |
dc.date.issued | 2017-02 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/69721 | - |
dc.description.abstract | Survivin is an inhibitor of apoptosis and is upregulated by Epstein-Barr virus (EBV) latent genes. Given the frequent association of EBV with lymphoid malignancies, survivin is expected to have prognostic value in diffuse large B-cell lymphoma (DLBCL). Thus, we measured the pretreatment serum level of survivin in DLBCL patients and analyzed its association with survival outcome and EBV status, as represented by EBV-encoded RNA (EBER) in DLBCL. Pretreatment serum survivin level was measured in patients registered in a prospective cohort study (n = 210), and serum survivin-positivity was defined as any detectable level of survivin. EBV status was determined using EBER in situ hybridization, and EBER-positivity was defined as 20% of examined cells showing nuclear positivity. Mean serum survivin level was higher in patients with relapsed or refractory disease than with responsive disease (59.89 pg/mL versus 17.34 pg/mL, P = 0.041). Serum survivin-positive patients had worse overall and progression- free survival (P = 0.023 and 0.022, respectively). Serum survivin positivity was associated with unfavorable characteristics including stage. In patients with non-germinal center B-cell type DLBCL, serum survivin-positive patients also had significantly worse survival than serum survivin-negative patients (P < 0.001). EBER-positivity was found in 6.7% (14/210) of patients, and EBER-positive patients had worse survival (P < 0.05). Patients having concomitant positivity for serum survivin and EBER expression (2.8%, 6/210) showed extremely poor prognosis. In the present era of rituximab in DLBCL, DLBCL with serum survivin positivity showed adverse clinical features and followed worse clinical course, especially in non-GCB subtype DLBCL. EBER-positivity was still associated with worse outcomes in DLBCL. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | IMPACT JOURNALS LLC | - |
dc.title | Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP | - |
dc.type | Article | - |
dc.identifier.doi | 10.18632/oncotarget.14636 | - |
dc.identifier.bibliographicCitation | ONCOTARGET, v.8, no.8, pp 13782 - 13791 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000395692000115 | - |
dc.identifier.scopusid | 2-s2.0-85013498849 | - |
dc.citation.endPage | 13791 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 13782 | - |
dc.citation.title | ONCOTARGET | - |
dc.citation.volume | 8 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | survivin | - |
dc.subject.keywordAuthor | epstein-barr virus | - |
dc.subject.keywordAuthor | diffuse large B-cell lymphoma | - |
dc.subject.keywordPlus | GENE-EXPRESSION | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | YM155 | - |
dc.subject.keywordPlus | SUPPRESSANT | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | EPSTEIN | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | THERAPY | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.